It all depends on what the PR says in the morning. If there are any new developments other than what we know now...it could be a gap to $10+.
Look at it this way... We are sitting on a potential SOC for AD. Not only that, but it's actually showing potential to halt or POSSIBLY reverse some of the effects of the disease. The average life expectancy of someone once diagnosed with AD is 5 years. If this stops the progression for a year, think of the reaction of the patients and their families. We just potentially added a whole year+ (20%) to their lives. That is wonderful.
And we are not done yet, because the trial (which is still ongoing) should continue to prove out the lasting benefit of taking 2-73. If we start a phase 3 trial and the results are in line with the smaller phase 2a we can make the argument that the phase 3 patients should continue to respond favorably to the treatment for "x" number of years.
The only reason the market hasn't embraced this approach is because it is different from the way BP is attacking the disease. It's assumed that they know more. But the proof is in the pudding.
Once mainstream media and BP embrace our idea based on the numbers our 2a is showing we are in for a huge push upward. Right now, in the phase we are in, and with the results we have, and considering the disease we are talking about, we should have a MC of over $1B (pps of ~$30). If we get a partner that changes dramatically.
The market had already demonstrated that it thinks that the value of an AD treatment is somewhere in the $10B-$20B range. If we enter phase 3 with a BP partner I feel that we should be valued at $10B (pps $300).
Next few weeks/months should tell the tale. And this is all not even considering the rest of the pipeline!!!
